News Articles
Latest articles, insights, and updates from the blog.
Contact Ketamine Tablet
Send corrections, provider questions, or advertising inquiries.
Why Patients Quit Ketamine Early—And How Tablets Factor In
New clinical data on NMDA antagonist dropout rates reveals how side effect management and route of administration affect treatment-resistant depression outcomes.
TRD Guidelines Spotlight Ketamine's Growing Role
Psychiatric Times highlights optimizing TRD treatments in 2026. Here's what it means for patients using oral ketamine tablets for depression.
Oral Ketamine Side Effects: What New TRD Data Tells Us
New clinical guidance on NMDA antagonist side effects and discontinuation rates offers key lessons for oral ketamine tablet users managing treatment-resistant depression.
NRx's Preservative-Free Ketamine Moves Closer to FDA OK
NRx Pharmaceuticals reports progress on its FDA application for preservative-free ketamine. Here's what this could mean for tablets, dosing, and patient access.
Trump EO on Psychedelics: What It Means for Ketamine
President Trump signed an executive order accelerating psychedelic research and access. Here's what oral ketamine tablet patients need to know about what changes.
NMDA Antagonist Side Effects: What Tablet Users Should Know
New research in Psychiatric Times breaks down side effect profiles and discontinuation rates for NMDA antagonists — here's what it means for oral ketamine tablet users.
Ketamine Side Effects & Dropout Rates: What Data Says
New analysis in Psychiatric Times urges data-driven ketamine dosing. Here's what the side-effect and dropout data means for oral tablet users.
Glutamate Pathway Treatments Reshape TRD Care in 2026
New research highlights how glutamate-targeting drugs like esketamine and ketamine are reshaping treatment-resistant depression care. Here's what it means for oral ketamine users.
Faster TRD Remission: What Dose Optimization Means
New clinical guidance on TRD care emphasizes rapid dose adjustment and symptom tracking — here's what it means for oral ketamine tablet patients.
Glutamate Pathway Treatments Reshaping TRD Care
New research highlights glutamate-based therapies like esketamine and ketamine tablets for treatment-resistant depression. Here's what it means for oral ketamine users.
Insurance Gaps Push Patients Toward Oral Ketamine
Ketamine insurance claim denied? How oral ketamine tablets offer an affordable depression treatment path, plus appeals tips and cash-pay tablet pricing.
How Doctors Choose TRD Treatments in 2026
How clinicians choose ketamine treatments for treatment-resistant depression in 2026, including when oral tablets are picked over IV, IM, or nasal spray.